Tacrolimus effect on rosacea.
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P<.05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.
Bamford
Joel T M
JT
Dermatology Section, St. Mary's/Duluth Clinic Health System, MN 55805, USA. jbamford@smdc.org
Elliott
Barbara A
BA
Haller
Irina V
IV
D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D012393:Rosacea / Q000188:drug therapy*; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016559:Tacrolimus